Johanna Röstin
Algemeen Adviseur bij VIVESTO AB
Profiel
Johanna Röstin currently works at Vivesto AB, as Chief Regulatory Officer.
Ms. Röstin also formerly worked at OxThera AB, as Director-CMC, Program Management & Regulatory and Swedish Orphan Biovitrum AB, as Manager-Global Senior Regulatory Affairs.
Ms. Röstin received her graduate degree from Royal Institute of Technology.
Actieve functies van Johanna Röstin
| Bedrijven | Functie | Begin |
|---|---|---|
| VIVESTO AB | Algemeen Adviseur | 01-10-2021 |
Eerdere bekende functies van Johanna Röstin
| Bedrijven | Functie | Einde |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Algemeen Adviseur | - |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Algemeen Adviseur | - |
Opleiding van Johanna Röstin
| Royal Institute of Technology | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| VIVESTO AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |